Роль Дефіциту Мелатоніну В Генезі Артеріальної Гіпертензії У Хворих На Хронічну Хворобу Нирок

Abstract

The study analyzed the prevalence of hypertension and impaired melatonin-forming function of the epiphysis in patients with stage 5 chronic kidney disease treated with hemodialysis. The relationship between epiphysis dysfunction and hypertension has been identified. 130 persons (50% of men) undergoing permanent hemodialysis treatment were examined. Controls were 20 healthy individuals. The determination of daytime and nighttime levels of melatonin in saliva and clinical and laboratory studies. As a result of the study it was found that for patients with stage 5 chronic kidney disease undergoing treatment, there is a frequent violation of melatonin-forming function of the pineal gland (84.6%) and hypertension (78%). In hemodialysis patients, blood pressure increases are age-dependent and are determined with salivary melatonin levels.

Meta-Analysis of Dependence of the Development of Experimental Renovascular Hypertension “2 Kidneys, 1 Clamp” on Lifestyle Factors

“…[130]. Также было показано, что нарушение эндогенной ночной секреции мелатонина связано с активацией внутрипочечной ренин-ангиотензиновой системы [131], а терапия мелатонином снижает дозировку антигипертензивных препаратов у пациентов с хронической болезнью почек [132]. Следует отметить, что работа в ночную смену способствует увеличению АД в среднем на 2,5 мм рт.…”

The coronavirus pandemic: could combining melatonin and glycyrrhizin be the solution for this ongoing emergency?

“…Further support to this potential adjuvant role of melatonin in COVID-19 infections comes from China itself, as summarized by Zhang and his colleagues (Zhang et al, 2020). Lastly, hypertension is among themost common morbidity in COVID-19 and melatonin possess antihypertensive properties (Mancia et al 2020, Petrova et al 2020). Melatonin also has reasonable docking scores as an angiotensin converting enzyme 2 (ACE2) inhibitor, and therefore, could offer added value especially in patients with end organ damage (Saadah et al, 2020).…”